Published on
A personalized immunotherapy has been awarded the FDA's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia.
Published on
NBC’s Dr. Nancy Snyderman reports on results of a study on the effectiveness of a targeted cellular therapy for leukemia, CTL019.
Published on
As new agents become more specific and target molecular characteristics of specific cancers, clinical trial enrollment may be restricted to children with relapsed cancers that harbor selected mutations.
Published on
60 Minutes Australia features CHOP’s Stephen Grupp, MD, discussing T cell therapy, how it helped one patient and offers hope for another.
Published on
The New York Times features a story on Emma Whitehead, the first child to receive CTL019, an experimental leukemia treatment.